1st Quarter - Report

FABIANI & COMPANY for EDISON PHARMACEUTICALS

Period 1st Quarter 2012 Filed Apr 20, 2012 Signed by Gary Martin, CFO

Official filing
Firm
FABIANI & COMPANY
Client
EDISON PHARMACEUTICALS
Income
$20,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Defense DEF

Defense Appropriations Act, developmental funding for therapeutics for hereditary and acquired mitochondrial diseases.

LobbyistCovered position, as disclosed
ELIZABETH BARROWS —

Contacted: Defense, Dept of (DOD); Defense Advanced Research Projects Agency (DARPA)

Health Issues HCR

Defense Appropriations Act, developmental funding for therapeutics for hereditary and acquired mitochondrial diseases.

LobbyistCovered position, as disclosed
ELIZABETH BARROWS —

Contacted: Defense Advanced Research Projects Agency (DARPA); Defense, Dept of (DOD)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.